Docetaxel-Associated Epiphora

Kintzel, Polly E; Michaud, Laura Boehnke; Lange, Marianne K.

doi:10.1592/phco.26.6.853

Cited by 44 publications

(27 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency and severity of epiphora increased with weekly administration of docetaxel compared with administration every 3 weeks [8]. In addition, ocular toxicity occurred in patients receiving a median or mean cumulative docetaxel dose of 300 or 400 mg/m 2 or a higher dose [9]. Cumulative doses of docetaxel in our cases were all more than 500 mg/m 2 .…”

Section: Discussionmentioning

confidence: 99%

“…Canalicular stenosis associated with docetaxel is most likely caused by secretion of docetaxel in the tear film and resultant chronic inflammation of the canaliculi due to direct contact with the drug as the tears travel through the canaliculi and the nasolacrimal duct to drain into the nose [4,9,10]. Importantly, epiphora occurs either with or without the presence of lacrimal duct obstruction [5], the latter being considered reactive tearing to ocular dryness [11].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epiphora in lung cancer patients receiving docetaxel: a case series

et al. 2014

View full text Add to dashboard Cite

BackgroundDocetaxel is a key antineoplastic drug for treatment of non-small cell lung cancer. Ocular adverse events of docetaxel include epiphora (excess tearing) and conjunctivitis. Epiphora has been reported to be associated with canalicular and nasolacrimal duct stenosis, but it is not necessarily caused by lacrimal duct obstruction.Case presentationWe encountered three Japanese non-small cell lung cancer patients who developed epiphora after the administration of docetaxel-based chemotherapy. One patient with lacrimal puncta stenosis showed improvement with probing and irrigation. The other two patients resolved following cessation of docetaxel or administration of artificial tears.ConclusionAs epiphora can interfere with activities of daily life and negatively affect quality of life, it is important for thoracic oncologists to be aware of this adverse event.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Epiphora in lung cancer patients receiving docetaxel: a case series

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In addition to being locally irritating or otherwise bothersome,64 epiphora may cause the tear film layer to become asymmetric (thickest at the inferior margin of the pupil), leading to coma-like aberrations and decreased optical quality (vertical “comet tails") after blinking 65…”

Section: Chemotherapeutic Agents Used Shortly After Bc Diagnosismentioning

confidence: 99%

Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

Eisner¹,

Luoh²

2011

Current Eye Research

View full text Add to dashboard Cite

This review concerns the effects on vision and the eye of medications prescribed at three phases of treatment for women with early-stage breast cancer (BC): (1) adjuvant cytotoxic chemotherapy, (2) adjuvant endocrine therapy, and (3) symptomatic relief. The most common side effects of cytotoxic chemotherapy are epiphora and ocular surface irritation, which can be caused by any of several different regimens. Most notably, the taxane docetaxel can lead to epiphora by inducing canalicular stenosis. The selective-estrogen-receptor-modulator (SERM) tamoxifen, long the gold-standard adjuvant-endocrine-therapy for women with hormone-receptor-positive BC, increases the risk of posterior subcapsular cataract. Tamoxifen also affects the optic nerve head more often than previously thought, apparently by causing subclinical swelling within the first 2 years of use for women older than ∼50 years. Tamoxifen retinopathy is rare, but it can cause foveal cystoid spaces that are revealed with spectral-domain optical coherence tomography (OCT) and that may increase the risk for macular holes. Tamoxifen often alters the perceived color of flashed lights detected via short-wavelength-sensitive (SWS) cone response isolated psychophysically; these altered perceptions may reflect a neural-response sluggishness that becomes evident at ∼2 years of use. The aromatase inhibitor (AI) anastrozole affects perception similarly, but in an age-dependent manner suggesting that the change of estrogen activity towards lower levels is more important than the low estrogen activity itself. Based on analysis of OCT retinal thickness data, it is likely that anastrozole increases the tractional force between the vitreous and retina. Consequently, AI users, myopic AI users particularly, might be at increased risk for traction-related vision loss. Because bisphosphonates are sometimes prescribed to redress AI-induced bone loss, clinicians should be aware of their potential to cause scleritis and uveitis occasionally. We conclude by suggesting some avenues for future research into the visual and ocular effects of AIs, particularly as relates to assessment of cognitive function.

show abstract

“…4,5 It has been approved for treatment of locally advanced and metastatic breast cancer, non-small cell lung cancer, androgen independent prostate cancer, advanced gastric cancer, and head and neck cancer. 6 DC is available commercially as Taxotere for intravenous administrations. Because of the poor solubility of DC in water, Polysorbate 80 is used in the formulation.…”

mentioning

confidence: 99%